|
1
|
Arbyn M, Castellsagué X, de Sanjosé S,
Bruni L, Saraiya M, Bray F and Ferlay J: Worldwide burden of
cervical cancer in 2008. Ann Oncol. 22:2675–2686. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Balacescu O, Balacescu L, Tudoran O, Todor
N, Rus M, Buiga R, Susman S, Fetica B, Pop L, Maja L, et al: Gene
expression profiling reveals activation of the FA/BRCA pathway in
advanced squamous cervical cancer with intrinsic resistance and
therapy failure. BMC Cancer. 14:2462014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lippert TH, Ruoff HJ and Volm M: Intrinsic
and acquired drug resistance in malignant tumors. The main reason
for therapeutic failure. Arzneimittelforschung. 58:261–264.
2008.PubMed/NCBI
|
|
6
|
Benjamin I, Saigo P, Finstad C, Takahashi
H, Federici M, Rubin SC and Boyd J: Expression and mutational
analysis of P53 in stage IB and IIA cervical cancers. Am J Obstet
Gynecol. 175:1266–1271. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim JW, Roh JW, Park NH, Song YS, Kang SB
and Lee HP: Polymorphism of TP53 codon 72 and the risk of cervical
cancer among Korean women. Am J Obstet Gynecol. 184:55–58. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Singh H, Sachan R, Devi S, Pandey SN and
Mittal B: Association of GSTM1, GSTT1, and GSTM3 gene polymorphisms
and susceptibility to cervical cancer in a North Indian population.
Am J Obstet Gynecol. 198:303.e1–6. 2008. View Article : Google Scholar
|
|
9
|
Cantor SB, Bell DW, Ganesan S, Kass EM,
Drapkin R, Grossman S, Wahrer DC, Sgroi DC, Lane WS, Haber DA and
Livingston DM: BACH1, a novel helicase-like protein, interacts
directly with BRCA1 and contributes to its DNA repair function.
Cell. 105:149–160. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu X, Chini CC, He M, Mer G and Chen J:
The BRCT domain is a phospho-protein binding domain. Science.
302:639–642. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cantor S, Drapkin R, Zhang F, Lin Y, Han
J, Pamidi S and Livingston DM: The BRCA1-associated protein BACH1
is a DNA helicase targeted by clinically relevant inactivating
mutations. Proc Natl Acad Sci USA. 101:2357–2362. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Peng M, Litman R, Jin Z, Fong G and Cantor
SB: BACH1 is a DNA repair protein supporting BRCA1 damage response.
Oncogene. 25:2245–2253. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tu Z, Aird KM, Bitler BG, Nicodemus JP,
Beeharry N, Xia B, Yen TJ and Zhang R: Oncogenic RAS regulates
BRIP1 expression to induce dissociation of BRCA1 from chromatin,
inhibit DNA repair, and promote senescence. Dev Cell. 21:1077–1091.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ma XD, Cai GQ, Zou W, Huang YH, Zhang JR,
Wang DT and Chen BL: First evidence for the contribution of the
genetic variations of BRCA1-interacting protein 1 (BRIP1) to the
genetic susceptibility of cervical cancer. Gene. 524:208–213. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ma XD, Cai GQ, Zou W, Huang YH, Zhang JR,
Wang DT and Chen BL: BRIP1 variations analysis reveals their
relative importance as genetic susceptibility factor for cervical
cancer. Biochem Biophys Res Commun. 433:232–236. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Narayan G, Arias-Pulido H, Nandula SV,
Basso K, Sugirtharaj DD, Vargas H, Mansukhani M, Villella J, Meyer
L, Schneider A, et al: Promoter hypermethylation of FANCF:
Disruption of Fanconi Anemia-BRCA pathway in cervical cancer.
Cancer Res. 64:2994–2997. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Levitus M, Waisfisz Q, Godthelp BC, de
Vries Y, Hussain S, Wiegant WW, Elghalbzouri-Maghrani E,
Steltenpool J, Rooimans MA, Pals G, et al: The DNA helicase BRIP1
is defective in Fanconi anemia complementation group J. Nat Genet.
37:934–935. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Song H, Ramus SJ, Kjaer SK, Hogdall E,
Dicioccio RA, Whittemore AS, McGuire V, Hogdall C, Jacobs IJ,
Easton DF, et al: Tagging single nucleotide polymorphisms in the
BRIP1 gene and susceptibility to breast and ovarian cancer. PLoS
One. 2:e2682007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rafnar T, Gudbjartsson DF, Sulem P,
Jonasdottir A, Sigurdsson A, Jonasdottir A, Besenbacher S, Lundin
P, Stacey SN, Gudmundsson J, et al: Mutations in BRIP1 confer high
risk of ovarian cancer. Nat Genet. 43:1104–1107. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Comparetto C and Borruto F: Cervical
cancer screening: A never-ending developing program. World J Clin
Cases. 3:614–624. 2015.PubMed/NCBI
|
|
21
|
Schiffman M, Wentzensen N, Wacholder S,
Kinney W, Gage JC and Castle PE: Human papillomavirus testing in
the prevention of cervical cancer. J Natl Cancer Inst. 103:368–383.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Salicrú SR, de la Torre JF and Gil-Moreno
A: The surgical management of early-stage cervical cancer. Curr
Opin Obstet Gynecol. 25:312–319. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Movva S, Rodriguez L, Arias-Pulido H and
Verschraegen C: Novel chemotherapy approaches for cervical cancer.
Cancer. 115:3166–3180. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Casagrande N, De Paoli M, Celegato M,
Borghese C, Mongiat M, Colombatti A and Aldinucci D: Preclinical
evaluation of a new liposomal formulation of cisplatin, lipoplatin,
to treat cisplatin-resistant cervical cancer. Gynecol Oncol.
131:744–752. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kote-Jarai Z, Jugurnauth S, Mulholland S,
Leongamornlert DA, Guy M, Edwards S, Tymrakiewitcz M, O'Brien L,
Hall A, Wilkinson R, et al: UKGPCS Collaborators; British
Association of Urological Surgeons' Section of Oncology: A
recurrent truncating germline mutation in the BRIP1/FANCJ gene and
susceptibility to prostate cancer. Br J Cancer. 100:426–430. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wong MW, Nordfors C, Mossman D,
Pecenpetelovska G, Avery-Kiejda KA, Talseth-Palmer B, Bowden NA and
Scott RJ: BRIP1, PALB2, and RAD51C mutation analysis reveals their
relative importance as genetic susceptibility factors for breast
cancer. Breast Cancer Res Treat. 127:853–859. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Leve F and Morgado-Díaz JA: Rho GTPase
signaling in the development of colorectal cancer. J Cell Biochem.
113:2549–2559. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tas PW, Gambaryan S and Roewer N: Volatile
anesthetics affect the morphology of rat glioma C6 cells via RhoA,
ERK, and Akt activation. J Cell Biochem. 102:368–376. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Struckhoff AP, Rana MK and Worthylake RA:
RhoA can lead the way in tumor cell invasion and metastasis. Front
Biosci (Landmark Ed). 16:1915–1926. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu M, Lang N, Chen X, Tang Q, Liu S,
Huang J, Zheng Y and Bi F: miR-185 targets RhoA and Cdc42
expression and inhibits the proliferation potential of human
colorectal cells. Cancer Lett. 301:151–160. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hamadmad SN and Hohl RJ: Erythropoietin
stimulates cancer cell migration and activates RhoA protein through
a mitogen-activated protein kinase/extracellular signal-regulated
kinase-dependent mechanism. J Pharmacol Exp Ther. 324:1227–1233.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
He M, Cheng Y, Li W, Liu Q, Liu J, Huang J
and Fu X: Vascular endothelial growth factor C promotes cervical
cancer metastasis via up-regulation and activation of
RhoA/ROCK-2/moesin cascade. BMC Cancer. 10:1702010. View Article : Google Scholar : PubMed/NCBI
|
